Kolon Life Science Inc. (KOSDAQ:102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,150
-1,550 (-5.81%)
Feb 21, 2025, 3:30 PM KST
11.04%
Market Cap 312.45B
Revenue (ttm) 147.98B
Net Income (ttm) -89.77B
Shares Out 12.42M
EPS (ttm) -7,681.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,975
Average Volume 34,341
Open 26,700
Previous Close 26,700
Day's Range 25,000 - 26,800
52-Week Range 16,780 - 29,300
Beta 0.38
RSI 54.79
Earnings Date Mar 13, 2025

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2000
Employees 420
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.